{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:33:44Z","timestamp":1787589224758,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Mayo Clinic Comprehensive Cancer Center","award":["P30 CA015083"],"award-info":[{"award-number":["P30 CA015083"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>The use of immune checkpoint inhibitors (ICIs) in kidney transplant recipients (KTR) for cancer treatment is limited by concerns of allograft rejection and uncertain oncologic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study of KTR with unresectable or metastatic malignancies treated between 2018 and 2025. The primary study cohort included 33 patients treated with ICI, whose outcomes were compared with 20 matched KTR treated with non-ICI systemic chemotherapy (SC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      KTR treated with ICI achieved an objective response rate of 36.4% (12\/33) versus 30.0% (6\/20) with SC, and a clinical benefit rate of 54.5% (18\/33) versus 35.0% (7\/20); neither difference was statistically significant (objective response rate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.77; clinical benefit rate\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.27). Disease progression occurred in 81.8% of ICI-treated patients and 95.0% of SC-treated patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.23), and death because of cancer progression occurred in 63.6% and 75.0%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.58). Median progression-free survival was 7.3 mo (95% confidence interval [CI], 4.3-10.8 mo) in the ICI group versus 4.1 mo (95% CI, 2.8-6.3 mo) in the SC group (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.156). Median overall survival was 15.1 mo (95% CI, 7.6-37.3 mo) with ICI versus 8.7 mo (95% CI, 4.9-14.8 mo) with SC (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.079). Posttreatment allograft rejection occurred in 12.1% of ICI-treated patients and 0.0% of SC-treated patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.29), with irreversible graft loss in 3.0%. Grade \u22652 immune-related adverse events occurred in 12.1% of ICI-treated patients, and no treatment-related deaths were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>ICI therapy was associated with a trend toward longer overall survival when compared with SC and with a low rate of rejection and allograft loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001992","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:09Z","timestamp":1787587209000},"page":"e1992","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor Therapy of Malignancy in Kidney Transplant Recipients: Analysis of Real-world Outcomes"],"prefix":"10.1097","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-2391","authenticated-orcid":false,"given":"Ali","family":"Rezazadeh","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Bianca","family":"Barbir","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Aboelatta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia-Denise","family":"Haivas","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Kavousi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron H.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kukla","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-8945","authenticated-orcid":false,"given":"Arkadiusz Z.","family":"Dudek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20260824","doi-asserted-by":"crossref","first-page":"13322","DOI":"10.3389\/ti.2024.13322","article-title":"Immune checkpoint inhibitor therapy for kidney transplant recipients\u2014a review of potential complications and management strategies.","volume":"37","author":"Barbir","year":"2024","journal-title":"Transpl Int"},{"key":"R2-20260824","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients.","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"R3-20260824","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMra2014530","article-title":"Long-term survival after kidney transplantation.","volume":"385","author":"Hariharan","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20260824","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000335799","article-title":"Photoprotection in transplant recipients.","volume":"43","author":"Surber","year":"2012","journal-title":"Curr Probl Dermatol"},{"key":"R5-20260824","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.abb.2011.01.004","article-title":"Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.","volume":"508","author":"Athar","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"R6-20260824","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20260824","doi-asserted-by":"crossref","first-page":"1041819","DOI":"10.3389\/fneph.2022.1041819","article-title":"Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.","volume":"2","author":"Van Meerhaeghe","year":"2022","journal-title":"Front Nephrol"},{"key":"R8-20260824","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.23.02570","article-title":"Checkpoint inhibition for kidney transplant recipients with advanced cutaneous carcinomas: an emerging standard for select patients.","volume":"42","author":"Koyfman","year":"2024","journal-title":"J Clin Oncol"},{"key":"R9-20260824","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"R10-20260824","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"R11-20260824","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma.","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"R12-20260824","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers.","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"R13-20260824","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R14-20260824","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R15-20260824","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/ajt.12716","article-title":"Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study.","volume":"14","author":"Vajdic","year":"2014","journal-title":"Am J Transplant"},{"key":"R16-20260824","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials.","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"R17-20260824","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2018.4406","article-title":"Aggressive squamous cell carcinoma in organ transplant recipients.","volume":"155","author":"Lanz","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R18-20260824","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.transproceed.2011.06.045","article-title":"Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?","volume":"43","author":"Arnau","year":"2011","journal-title":"Transplant Proc"},{"key":"R19-20260824","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors.","volume":"9","author":"Gupta","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20260824","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","article-title":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.","volume":"16","author":"Kao","year":"2025","journal-title":"Nat Commun"},{"key":"R21-20260824","doi-asserted-by":"crossref","first-page":"151500","DOI":"10.1016\/j.semnephrol.2024.151500","article-title":"Immune checkpoint inhibitors in recipients of renal allografts.","volume":"44","author":"Venkataraman","year":"2024","journal-title":"Semin Nephrol"},{"key":"R22-20260824","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy.","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"R23-20260824","doi-asserted-by":"crossref","first-page":"e1851","DOI":"10.1097\/TXD.0000000000001851","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a French multicenter retrospective cohort study.","volume":"11","author":"Legris","year":"2025","journal-title":"Transplant Direct"},{"key":"R24-20260824","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaoncol.2025.2374","article-title":"Outcomes of solid organ transplant recipients with advanced cancers receiving immune checkpoint inhibitors: a systematic review and individual participant data meta-analysis.","volume":"11","author":"Saleem","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TXD.0000000000001992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:12Z","timestamp":1787587212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TXD.0000000000001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001992","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2026-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}